Apolipoprotein B: the Rosetta Stone of lipidology.

Tamara Glavinovic, Allan D Sniderman

Current opinion in endocrinology, diabetes, and obesity 2021 Apr 01

filter terms:

This review summarizes the evidence that apolipoprotein B (apoB) integrates the conventional lipid markers - total cholesterol, triglycerides, LDL-cholesterol, and non-HDL-cholesterol - into a single index that accurately and simply quantitates the atherogenic risk due to the apoB lipoprotein particles. Marked hypertriglyceridemia remains the essential signal for hyperchylomicronemia and potential pancreatitis. However, with the exception of Lp(a) and the abnormal cholesterol-enriched remnant particles that are the hallmark of type III hyperlipoproteinemia, recent evidence from discordance analyses and Mendelian randomization indicate that apoB integrates the risk due to the atherogenic lipoprotein particles because all LDL particles are, within the limits of our ability to measure any differences, equally atherogenic and all, except the largest VLDL particles are, within the limits of our ability to measure any differences, equally atherogenic. Measuring apoB as well as the conventional lipids is essential for accurate diagnosis. For almost all follow-up, however, apoB is all that need be measured. ApoB is the Rosetta Stone of lipidology because dyslipoproteinemia cannot be understood unless apoB is measured. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Citation

Tamara Glavinovic, Allan D Sniderman. Apolipoprotein B: the Rosetta Stone of lipidology. Current opinion in endocrinology, diabetes, and obesity. 2021 Apr 01;28(2):90-96